Researchers Richard E. Carson, PhD, Mika Naganawa, PhD, and colleagues from the Yale School of Medicine, in collaboration with Pfizer, have reported the first in-human assessment of the radiotracer 18F-PF-05270430 – the first PET ligand to exhibit good properties for imaging and quantifying PDE2A in vivo. The enzyme phosphodiesterase-2A (PDE2A) is an important target in the development of drugs to treat patients with cognitive impairments. A PDE2A PET tracer could enable evaluation of disease-specific changes and testing of candidate compounds.
Submitted by Liz Pantani on July 06, 2018